Repeated courses of Rituximab in chronic ITP: Three different regimens

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 661-665

  Hasan, Aisha ^a,d   Michel, Marc ^b   Patel, Vivek ^a   Stasi, Roberto ^c   Cunningham Rundles, Susanna ^a   Leonard, John P ^a   Bussel, James ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b HENRI MONDOR HOSPITAL   (France)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALLERGIC REACTION; ARTICLE; CANCER PATIENT; CANCER RELAPSE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70349496075     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21512     Document Type: Article

References (38)

1. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet 1997;349:1531-1536.
2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
3. Beardsley DS. Pathophysiology of immune thrombocytopenic purpura. Blood Rev 2002;16:13-14.
4. Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002;16:9-12. (Pubitemid 34293544)
5. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887-895. (Pubitemid 36917780)
6. Mcmillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-1369. (Pubitemid 38168649)
7. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995;98:436-442.
8. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000;160:1630-1638. (Pubitemid 30367902)
9. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American society of hematology. Blood 1996;88:3-40.
10. The American Society of Hematology ITP Practice Guideline Panel. Diagnosis and treatment of idiopathic thrombocytopenic purpura: Recommendations of the American society of hematology. Ann Intern Med 1997;126:319-326.
11. Vianelli N, Galli M, De Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: Long-term results of 402 cases. Haematologica 2005;90:72-77. (Pubitemid 40193756)
12. Zoghlami-Rintelen C, Weltermann A, Bittermann C, et al. Efficacy and safety of splenectomy in adult chronic immune thrombocytopenia. Ann Hematol 2003;82:290-294. (Pubitemid 36701423)
13. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004;22:4711-4716. (Pubitemid 41185080)
14. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423. (Pubitemid 40223656)
15. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033. (Pubitemid 46224009)
16. O'brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170.
17. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
18. Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
19. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952-957.
20. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000;27:99-103. (Pubitemid 32164602)
21. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125:232-239. (Pubitemid 38534976)
22. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-2642.
23. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005;78:275-280. (Pubitemid 40471119)
24. Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, et al. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: A longterm follow-up analysis. Ann Hematol 2007;86:871-877.
25. Penalver FJ, Jimenez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 2006;85:400-406.
26. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: Results of a prospective multicenter phase 2 study. Blood 2008;112:999-1004.
27. Patel VMN, Cooper N, Stasi R, et al. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 Year. Blood 2006;108:1062.
28. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 2009;113:4834-4840.
29. Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008;93:930-933. (Pubitemid 351821733)
30. Fairweather H, Tuckfield A, Grigg A. Abbreviated dose rituximab for immunemediated hematological disorders. Am J Hematol 2008;83:554-557. (Pubitemid 351874871)
31. Mcmillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. N Engl J Med 2001;344:1402-1403. (Pubitemid 32378402)
32. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995;85:351-358.
33. Kuwana M, Iki S, Urabe A. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab. Am J Hematol 2007;82:846-848. (Pubitemid 350194520)
34. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110:2924-2930. (Pubitemid 350006946)
35. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2008;112:1147-1150.
36. Zhao C, Li X, Zhang F, Wang L, et al. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93:1428-1430.
37. Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-1124. (Pubitemid 37173694)
38. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-1095. (Pubitemid 46202263)